Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

APEN - Apollo Endosurgery Inc


Close
10
0.080   0.800%

Share volume: 0
Last Updated: Mon 03 Apr 2023 10:00:00 PM CEST
Biological Product (except Diagnostic) Manufacturing : -3.41%

PREVIOUS CLOSE
CHG
CHG%

$9.92
0.08
0.81%
This ticker is disabled and data are no longer maintained and up to date.
Fundamental analysis
17%
Profitability 0%
Dept financing 43%
Liquidity 29%
Performance 25%
Company vs Stock growth
vs
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$10.00
P/E Ratio 
0.00
DAY RANGE
N/A - $10.00
EPS 
$0.00
52 WEEK RANGE
$0.00 - $0.00
52 WEEK CHANGE
$0.00
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
57.972 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$0
AVERAGE 30 VOLUME 
$0
Company detail
CEO: Gary Atkinson
Region: US
Website: apolloendo.com
Employees: 202
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Biological Product (except Diagnostic) Manufacturing
Sector: Manufacturing

Apollo Endosurgery, Inc. is a medical technology company focused on less invasive therapies to treat various gastrointestinal conditions, ranging from gastrointestinal defect repairs to the interventional treatment of obesity. Apollo's device-based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo's products are offered in over 75 countries today and include the X-Tack™ Endoscopic HeliX Tacking System, the OverStitch™ Endoscopic Suturing System, the OverStitch Sx™ Endoscopic Suturing System, and the ORBERA® Intragastric Balloon.

Recent news